Comparison 1. Non‐platinum single‐agent versus non‐platinum combination.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival (OS)	5		Hazard Ratio (Random, 95% CI)	0.92 [0.72, 1.17]
2 1‐Year survival rate (OS1y)	4	993	Risk Ratio (M‐H, Random, 95% CI)	0.88 [0.73, 1.07]
3 Progression‐free survival	4		Hazard Ratio (Fixed, 95% CI)	0.94 [0.83, 1.07]
4 Objective response rate (ORR)	5	1014	Risk Ratio (M‐H, Fixed, 95% CI)	1.79 [1.41, 2.26]
5 Grade 3 and 4 hematological adverse events (AEs)	5		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 Anemia	5	1064	Risk Ratio (M‐H, Fixed, 95% CI)	1.18 [0.57, 2.40]
5.2 Neutropenia	5	1064	Risk Ratio (M‐H, Fixed, 95% CI)	1.19 [0.93, 1.54]
5.3 Febrile neutropenia	4	995	Risk Ratio (M‐H, Fixed, 95% CI)	0.34 [0.04, 3.20]
5.4 Thrombocytopenia	4	995	Risk Ratio (M‐H, Fixed, 95% CI)	1.58 [0.82, 3.04]
6 Grade 3 and 4 non‐hematological adverse events (AEs)	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
6.1 Fatigue	4	995	Risk Ratio (M‐H, Fixed, 95% CI)	1.16 [0.69, 1.96]
6.2 Emesis	4	995	Risk Ratio (M‐H, Fixed, 95% CI)	1.73 [0.68, 4.43]
6.3 Diarrhea	3	875	Risk Ratio (M‐H, Fixed, 95% CI)	3.96 [0.36, 43.41]
6.4 Constipation	3	307	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.06, 15.62]
6.5 Mucositis/Stomatitis	4	995	Risk Ratio (M‐H, Fixed, 95% CI)	0.66 [0.07, 6.30]